Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Astepro® Allergy and Children’s Astepro Allergy (azelastine) – New partial over-the-counter approval

The FDA announced the approval of partial over-the-counter (OTC) use of Bayer’s Astepro Allergy and Children’s Astepro Allergy (azelastine) 0.15%, for the temporary relief of nasal congestion, runny nose, sneezing and itchy nose due to hay fever or other upper respiratory allergies in adults and children 6 years of age and older. June 17, 2021

Pradaxa® (dabigatran etexilate) – New formulation approval, new indication

The FDA announced the approval of Boehringer Ingelheim’s Pradaxa (dabigatran) oral pellets, for the treatment of venous thromboembolic events (VTE) in pediatric patients aged 3 months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days and to reduce the risk of recurrence of VTE in pediatric patients aged 3 months to less than 12 years of age who have been previously treated. June 22, 2021

Soaanz® (torsemide) – New drug approval

The FDA approved Sarfez Pharmaceuticals’ Soaanz (torsemide), in adults for the treatment of edema associated with heart failure or renal disease. June 14, 2021

StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat) – New orphan drug approval

The FDA announced the approval of Mallinckrodt’s StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat), for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). June 15, 2021

Intelence® (etravirine) – First-time generic

Amneal launched an AB-rated generic version of Jansse’s Intelence (etravirine) tablets. June 15, 2021

Ayvakit™ (avapritinib) – New indication

Blueprint Medicines announced the FDA approval of Ayvakit (avapritinib), for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). June 16, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.